BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Thalassemia clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for thalassemia: 44 (22 sponsors; 0 newly posted in the last 180 days, 3 stopped in the last 180 days; 0 new-entrant sponsors). Momentum score 8, rank 80 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 4, Phase 1 3, Phase 2 14, Phase 3 9, Phase 4 3, N/A 11.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Agios Pharmaceuticals, Inc. AGIO | 6 | P4 1, P3 4, P2 1 | 0 | 0 |
| Vertex Pharmaceuticals Incorporated VERX | 3 | P3 3 | 0 | 0 |
| Celgene | 2 | P2 1, P3 1 | 0 | 0 |
| Novo Nordisk A/S NVO | 1 | P3 1 | 0 | 0 |
| Bristol-Myers Squibb BMY | 5 | P2 2, NA 2, P4 1 | 0 | 0 |
| CorrectSequence Therapeutics Co., Ltd | 4 | P2 1, NA 2, EARLY_P1 1 | 0 | 0 |
| Shenzhen Hemogen | 4 | EARLY_P1 3, P1 1 | 0 | 1 |
| Bioray Laboratories | 3 | NA 2, P2 1 | 0 | 0 |
| Editas Medicine, Inc. EDIT | 2 | NA 1, P2 1 | 0 | 0 |
| Genetix Biotherapeutics Inc. | 2 | NA 2 | 0 | 0 |
| Elpen Pharmaceutical Co. Inc. | 1 | NA 1 | 0 | 0 |
| Imara, Inc. | 1 | P2 1 | 0 | 0 |
| Kanglin Biotechnology (Hangzhou) Co., Ltd. | 1 | P2 1 | 0 | 0 |
| Kind Pharmaceuticals LLC | 1 | P2 1 | 0 | 1 |
| Lantu Biopharma | 1 | P2 1 | 0 | 0 |
| Mabwell (Shanghai) Bioscience Co., Ltd. | 1 | P1 1 | 0 | 0 |
| Novartis Pharmaceuticals NVS | 1 | P4 1 | 0 | 0 |
| Pharmacosmos A/S | 1 | P2 1 | 0 | 0 |
| Regeneron Pharmaceuticals REGN | 1 | P2 1 | 0 | 1 |
| Sangamo Therapeutics SGMOQ | 1 | NA 1 | 0 | 0 |
| ScinnoHub Pharmaceutical Co., Ltd. | 1 | P2 1 | 0 | 1 |
| Shanghai BDgene Co., Ltd. | 1 | P1 1 | 0 | 1 |
Recently stopped trials
- NCT07401823 Fulcrum Therapeutics - terminated: Sponsor Decision Open-Label Extension Study to Pioneer Study 6058-SCD-101
- NCT07681440 Bristol-Myers Squibb - terminated: Insufficient enrollment A Study to Evaluate Luspatercept Utilization in Patients With Lower Risk Myelodysplastic Syndromes or Beta-thalassemia
- NCT07431398 Fulcrum Therapeutics - terminated: Sponsor decision Single-dose Pharmacokinetics of Pociredir in Participants With Sickle Cell Disease
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P2 | Kind Pharmaceuticals LLC | NCT06302491 A Study of Safety and Efficiency of AND017 in Patients With β-thalassemia | β -Thalassemia | recruiting | 64 |
| 2026-12-03 est. | P2 | Regeneron Pharmaceuticals REGN | NCT06421636 A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participant | Non-Transfusion Dependent Beta-Thalassemia (NTDT) | active not recruiting | 19 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-10-20 est. | P1/P2 | Bioray Laboratories | NCT05577312 Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia | Beta-Thalassemia | active not recruiting | 39 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "thalassemia"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.